Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
September 1, 2010 source: xconomy Brad Webb, Venture Partner at Claremont Creek Ventures, was featured today on the xcononomy website discussing the implications for venture investment of the recent judicial ruling regarding federal funding for stem cell research. Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research has thrown academic research circles into a state of confusion. This has caught the attention of the VC community, . . .
→ Read full post: Will the Stem Cell Ruling Affect Venture Capital Investing?